Research on mRNA Expression and Clinical Significance of Peroxisome Proliferator-activated Receptorγ and Vascular Endothelial Growth Factor C in Gastric Cancer Patients_West China Medical Journal

Authors：

LI Xiaojun ¹ , WU Xiaoting ² , WANG Xiaoqiang ¹ , LONG Yanbin ¹ , DUAN Xianglong ¹ , ZHANG Ruipeng ¹

1. Department of General Surgery, Shaanxi Provincial People′s Hospital, Xi′an, Shaanxi 710068, P. R. China; 2. Department of Gastro-intestinal Surgery Center, West China Hospital, Sichuan university, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

Keywords：

胃癌; 氧化酶增殖因子活化受体; 血管内皮生长因子C; 逆转录-聚合酶链反应

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　研究过氧化酶增殖因子活化受体γ（peroxisome proliferator-activated receptor gamma， PPARγ）和血管内皮生长因子C（vascular endothelial growth factor C， VEGF-C）在胃癌组织中表达的相关性，分析其表达与临床病理因素之间的关系。　方法　 2005年3月-2009年3月间采用逆转录-聚合酶链反应方法检测36例胃癌手术标本中PPARγ和VEGF-C mRNA的表达，同时选取相同患者的胃正常组织作为对照。　结果　 PPARγ mRNA在胃癌中的表达量高于癌旁正常组织，两者的差异有统计学意义（P=0.007）；VEGF-C在胃癌中的表达量高于癌旁正常组织，两者的差异有统计学意义（P=0.004）；PPARγ的表达与VEGF-C表达无关联性（r=0.135，P=0.414）；PPARγ表达与胃癌组织中浸润程度有关（χ2=4.620，P=0.032）、淋巴结转移有关（χ2=15.753，P=0.000）和临床病理分期有关（χ2=4.610，P=0.032）；VEGF-C表达与胃癌组织中淋巴结转移有关（χ2=4.729，P=0.030）、远处转移有关（χ2=4.064，P=0.044）和临床病理分期有关（χ2=6.300，P=0.012）。　结论　 PPARγ和VEGF-C可能在胃癌新生淋巴管形成中起重要作用，两者的表达水平与胃癌患者的病情判断及预后评价密切相关。
【Abstract】　Objective　 To investigate the significance of expressions of peroxisome proliferator-activated receptor gamma (PPARγ) and vascular endothelial growth factor C (VEGF-C) in gastric carcinoma as well as their correlation, and to study the relationship between the expressions and clinicopathologic characteristics of gastric carcinoma. 　Methods　 Thirty-six pairs of normal mucosa and cancer specimens were obtained from patients who had undergone gastric operation for primary gastric carcinoma and subjected to reverse transcription-ploymerase chain reaction (RT-PCR) for PPARγ and VEGF-C mRNA detection.　Results　 The positive rate and level of PPARγ mRNA expression were higher in gastric cancer tissues than those in normal gastric mucosa (P=0.007). The positive rate and level of VEGF-C mRNA expression were also higher in gastric cancer tissues than those in normal gastric mucosa (P=0.004). Simultaneously, the expression of PPARγ was not correlated with that of VEGF-C (r=0.135, P=0.414), while the highly productions of PPARγ and VEGF-C in gastric carcinomas were both associated with the lymph node metastasis and the clinical stage (P lt;0.05).　Conclusion　 PPARγ and VEGF-C may play an important role in the lymphangio-genesis of gastric cancer, and united detection of PPARγ and VEGF-C expressions may be correlated with making diagnosis, evaluating prognosis in patients with gastric cancer at the same time.

Citation： LI Xiaojun,WU Xiaoting,WANG Xiaoqiang,LONG Yanbin,DUAN Xianglong,ZHANG Ruipeng. Research on mRNA Expression and Clinical Significance of Peroxisome Proliferator-activated Receptorγ and Vascular Endothelial Growth Factor C in Gastric Cancer Patients. West China Medical Journal, 2011, 26(9): 1318-1322. doi: Copy

1.	Itakura E, Yamamoto H, Oda Y, et al. VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? [J]. Virchows Arch, 2009, 454(3): 317-325.
2.	Breslin JW, Gaudreault N, Watson KD, et al. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism[J]. Am J Physiol Heart Circ Physiol, 2007, 293(1): H709-H718.
3.	Han FH, Li HM, Zheng DH, et al. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma[J]. Eur J Surg Oncol, 2010, 36(12): 1172-1179.
4.	Saharinen P, Tammela T, Karkkainen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation[J]. Trends Immunol, 2004, 25(7): 387-395.
5.	Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms[J]. Annu Rev Cell Dev Biol, 2005, 21: 457-483.
6.	Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease[J]. J Invest Dermatol, 2006, 126(10): 2167-2177.
7.	Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta analysis of the literature[J]. Br J Cancer, 2006, 94(12):1823-1832.
8.	Alabi AA, Suppiah A, Madden LA, et al. Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients[J]. Int J Colorectal Dis, 2009, 24(3): 269-274.
9.	George G, Chen HX, Janet FY, et al. 15 - hydroxy - eicosate traenoic acid arrests growth of colorectal cancer cells via aperoxisome poliferator-activated receptor gamma depengent pathway[J]. Intern J Cancer, 2003, 107(5): 837-843.
10.	Pandhare J, Cooper SK, Phang JM. Proline Oxidase, a p roapop toticgene is induced by troglitazone: Evidence for both PPAR - dependent and independ - entmechanisms[J]. J Biol Chem, 2006, 281(4): 2044-2052.
11.	Moss PE, Lyles BE, Stewart LV. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells[J]. Exp Cell Res, 2010, 316(20): 3478-3488.
12.	Colin C, Salamone S, Grillier-Vuissoz I, et al. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone dependent and hormone-independent breast cancer cell lines[J]. Breast Cancer Res Treat, 2010, 124(1): 101-110.
13.	Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis[J]. J Clin Invest, 2002, 110(7): 923-932.
14.	李小军, 张清华, 罗婷, 等. 胃癌组织中过氧化物酶增殖因子活化受体与VEGF mRNA 表达的相关性和意义[J]. 中国普外基础与临床杂志, 2008, 15(7): 498-502.

1. 　Itakura E, Yamamoto H, Oda Y, et al. VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? [J]. Virchows Arch, 2009, 454(3): 317-325.
2. 　Breslin JW, Gaudreault N, Watson KD, et al. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism[J]. Am J Physiol Heart Circ Physiol, 2007, 293(1): H709-H718.
3. 　Han FH, Li HM, Zheng DH, et al. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma[J]. Eur J Surg Oncol, 2010, 36(12): 1172-1179.
4. 　Saharinen P, Tammela T, Karkkainen MJ, et al. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation[J]. Trends Immunol, 2004, 25(7): 387-395.
5. 　Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms[J]. Annu Rev Cell Dev Biol, 2005, 21: 457-483.
6. 　Cueni LN, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease[J]. J Invest Dermatol, 2006, 126(10): 2167-2177.
7. 　Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta analysis of the literature[J]. Br J Cancer, 2006, 94(12):1823-1832.
8. 　Alabi AA, Suppiah A, Madden LA, et al. Preoperative serum levels of serum VEGF-C is associated with distant metastasis in colorectal cancer patients[J]. Int J Colorectal Dis, 2009, 24(3): 269-274.
9. 　George G, Chen HX, Janet FY, et al. 15 - hydroxy - eicosate traenoic acid arrests growth of colorectal cancer cells via aperoxisome poliferator-activated receptor gamma depengent pathway[J]. Intern J Cancer, 2003, 107(5): 837-843.
10. 　Pandhare J, Cooper SK, Phang JM. Proline Oxidase, a p roapop toticgene is induced by troglitazone: Evidence for both PPAR - dependent and independ - entmechanisms[J]. J Biol Chem, 2006, 281(4): 2044-2052.
11. 　Moss PE, Lyles BE, Stewart LV. The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells[J]. Exp Cell Res, 2010, 316(20): 3478-3488.
12. 　Colin C, Salamone S, Grillier-Vuissoz I, et al. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone dependent and hormone-independent breast cancer cell lines[J]. Breast Cancer Res Treat, 2010, 124(1): 101-110.
13. 　Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis[J]. J Clin Invest, 2002, 110(7): 923-932.
14. 　李小军, 张清华, 罗婷, 等. 胃癌组织中过氧化物酶增殖因子活化受体与VEGF mRNA 表达的相关性和意义[J]. 中国普外基础与临床杂志, 2008, 15(7): 498-502.

West China Medical Journal

Research on mRNA Expression and Clinical Significance of Peroxisome Proliferator-activated Receptorγ and Vascular Endothelial Growth Factor C in Gastric Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Format

Content